CfDNA as a prognostic marker of response to taxane based chemotherapy in patients with prostate cancer

Journal of Urology

Volumn 194, Issue 4, 2015, Pages 966-971

  Kienel, Alexandra ^a   Porres, Daniel ^a   Heidenreich, Axel ^a   Pfister, David ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

DNA; mortality; prognosis; prostatic neoplasms; taxane

Indexed keywords

CABAZITAXEL; DNA; DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; TAXANE; TAXOID; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENCE FREE SURVIVAL; SERUM; AGED; BLOOD; GENETICS; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDY; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BRIDGED COMPOUNDS; DNA, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS;

EID: 84941598791     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.04.055     Document Type: Article

References (24)

1. U. Wolf, B. Barnes, J. Bertz, and et al. The (German) Center for Cancer Registry Data (ZfKD) at the Robert Koch Institute (RKI) in Berlin Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 54 2011 1229
2. J. Haberland, J. Bertz, U. Wolf, and et al. German cancer statistics 2004 BMC Cancer 10 2010 52
3. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89
4. S.A. Leon, B. Shapiro, D.M. Sklaroff, and et al. Free DNA in the serum of cancer patients and the effect of therapy Cancer Res 37 1977 646
5. M. Stroun, J. Lyautey, C. Lederrey, and et al. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release Clin Chim Acta 313 2001 139
6. G. Sozzi, D. Conte, M. Leon, and et al. Quantification of cell free circulating DNA as a diagnostic marker in lung cancer J Clin Oncol 21 2003 3902
7. T.L. Wu, D. Zhang, J.H. Chia, and et al. Cell free DNA: measurement in various carcinomas and establishment of normal reference range Clin Chim Acta 321 2002 77
8. J. Feng, F. Gang, X. Li, and et al. Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen Int Urol Nephrol 45 2013 1023
9. P.J. Bastian, G.S. Palapattu, S. Yegnasubramanian, and et al. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy Clin Cancer Res 13 2007 5361
10. J.S. De Bono, S. Oudard, M. Ozguroglu, and et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147
11. I.F. Tannock, R. de Wit, W.R. Berry, and et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502
12. A.J. Armstrong, E. Garrett-Mayer, Y.C. Ou Yang, and et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer J Clin Oncol 25 2007 3965
13. D.R. Berthold, G.R. Pond, F. Soban, and et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2008 242
14. J.S. De Bono, H.I. Scher, R.B. Montgomery, and et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 2008 6302
15. P. Olbert, A. Hegele, P. Krauter, and et al. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel Anticancer Drugs 17 2006 993
16. T. Nelius, and S. Filleur PSA surge/flare up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy Prostate 69 2009 1802
17. Y.Y. Qu, B. Dai, Y.Y. Kong, and et al. Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy Asian J Androl 15 2013 110
18. A.J. Armstrong, M.A. Eisenberger, S. Halabi, and et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer Eur Urol 61 2012 549
19. S. Kwee, M.A. Song, I. Cheng, and et al. Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer Clin Trans Sci 5 2012 65
20. A.A. Kamat, F.Z. Bischoff, D. Dang, and et al. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma Cancer Biol Ther 5 2006 1369
21. N. Umetani, S. Hiramatsu, and D. Hoon Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation Ann N Y Acad Sci 1075 2006 299
22. S. Halabi, E.J. Small, P.W. Kantoff, and et al. Prognostic model predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21 2003 1232
23. G. Sonpavde, G. Pond, W. Berry, and et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy Urol Oncol 30 2012 607
24. A.J. Armstrong, E. Garrett-Mayer, R. de Wit, and et al. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer Clin Cancer Res 16 2010 203